FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048598834> ?p ?o ?g. }

• W2048598834 endingPage "437" @default.
• W2048598834 startingPage "437" @default.
• W2048598834 abstract "February 2013 US treatment guidelines recommend the once-daily tablet of efavirenz/emtricitabine/tenofovir (Atripla®) as a preferred regimen and the once-daily tablet of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild™) as an alternative regimen for first-line treatment of human immunodeficiency virus (HIV). This study assessed the clinical and economic trade-offs involved in using Atripla compared with Stribild as first-line antiretroviral therapy in HIV-infected US adults.A Markov cohort model was developed to project lifetime health-related outcomes, costs, quality-adjusted life years (QALYs), and cost-effectiveness of Stribild compared with Atripla as first-line antiretroviral therapy in HIV-1-infected US patients. Patients progressed in 12-week cycles through second-line, third-line, and nonsuppressive therapies, acquired immune deficiency syndrome, and death. Baseline characteristics and first-line virologic suppression, change in CD4 count, and adverse effects (lipid, central nervous system, rash, renal) were based on 48-week clinical trial results. These results demonstrated equivalent virologic suppression between the two regimens. Point estimates for virologic suppression (favoring Stribild) were used in the base case, and equivalency was used in the scenario analysis. Published sources and expert opinion were used to estimate costs, utilities, risk of acquired immune deficiency syndrome, mortality, subsequent-line CD4 count, clinical efficacy, and adverse events. Costs were reported in 2012 US dollars. Sensitivity analyses were conducted to assess robustness of results.Compared with patients initiating Atripla, patients initiating Stribild were estimated to have higher lifetime costs. Stribild added 0.041 QALYs over a lifetime at an additional cost of $6,886, producing an incremental cost-effectiveness ratio of $166,287/QALY gained. Results were most sensitive to first-line response rates, product costs, and likelihood of renal adverse events. When equivalent efficacy was assumed, Atripla dominated Stribild with lower costs and greater QALYs.At a societal willingness to pay of $100,000/QALY, Stribild was not cost-effective in the base case compared with Atripla for first-line HIV treatment." @default.
• W2048598834 created "2016-06-24" @default.
• W2048598834 creator A5011583990 @default.
• W2048598834 creator A5017807808 @default.
• W2048598834 creator A5042995852 @default.
• W2048598834 creator A5050697666 @default.
• W2048598834 creator A5057792252 @default.
• W2048598834 creator A5068614908 @default.
• W2048598834 date "2013-09-01" @default.
• W2048598834 modified "2023-10-01" @default.
• W2048598834 title "Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US" @default.
• W2048598834 cites W1710217780 @default.
• W2048598834 cites W1964761588 @default.
• W2048598834 cites W1967347018 @default.
• W2048598834 cites W1985722970 @default.
• W2048598834 cites W1989932163 @default.
• W2048598834 cites W1995517770 @default.
• W2048598834 cites W2005218441 @default.
• W2048598834 cites W2020692439 @default.
• W2048598834 cites W2038002163 @default.
• W2048598834 cites W2042208706 @default.
• W2048598834 cites W2045131275 @default.
• W2048598834 cites W2047833210 @default.
• W2048598834 cites W2066141617 @default.
• W2048598834 cites W2069079087 @default.
• W2048598834 cites W2088008322 @default.
• W2048598834 cites W2097257127 @default.
• W2048598834 cites W2106164053 @default.
• W2048598834 cites W2127448855 @default.
• W2048598834 cites W2139772076 @default.
• W2048598834 cites W2145467751 @default.
• W2048598834 cites W2147210767 @default.
• W2048598834 cites W2150504993 @default.
• W2048598834 cites W2165750096 @default.
• W2048598834 cites W2189074617 @default.
• W2048598834 cites W2418444286 @default.
• W2048598834 doi "https://doi.org/10.2147/ceor.s47486" @default.
• W2048598834 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3770712" @default.
• W2048598834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24039438" @default.
• W2048598834 hasPublicationYear "2013" @default.
• W2048598834 type Work @default.
• W2048598834 sameAs 2048598834 @default.
• W2048598834 citedByCount "4" @default.
• W2048598834 countsByYear W20485988342014 @default.
• W2048598834 countsByYear W20485988342016 @default.
• W2048598834 countsByYear W20485988342018 @default.
• W2048598834 countsByYear W20485988342022 @default.
• W2048598834 crossrefType "journal-article" @default.
• W2048598834 hasAuthorship W2048598834A5011583990 @default.
• W2048598834 hasAuthorship W2048598834A5017807808 @default.
• W2048598834 hasAuthorship W2048598834A5042995852 @default.
• W2048598834 hasAuthorship W2048598834A5050697666 @default.
• W2048598834 hasAuthorship W2048598834A5057792252 @default.
• W2048598834 hasAuthorship W2048598834A5068614908 @default.
• W2048598834 hasBestOaLocation W20485988341 @default.
• W2048598834 hasConcept C126322002 @default.
• W2048598834 hasConcept C142462285 @default.
• W2048598834 hasConcept C159047783 @default.
• W2048598834 hasConcept C197934379 @default.
• W2048598834 hasConcept C2522874641 @default.
• W2048598834 hasConcept C2777068322 @default.
• W2048598834 hasConcept C2777869810 @default.
• W2048598834 hasConcept C2778375690 @default.
• W2048598834 hasConcept C2778414717 @default.
• W2048598834 hasConcept C2779778239 @default.
• W2048598834 hasConcept C2780524789 @default.
• W2048598834 hasConcept C2780593183 @default.
• W2048598834 hasConcept C2781413609 @default.
• W2048598834 hasConcept C2781432083 @default.
• W2048598834 hasConcept C2993143319 @default.
• W2048598834 hasConcept C3013748606 @default.
• W2048598834 hasConcept C71924100 @default.
• W2048598834 hasConceptScore W2048598834C126322002 @default.
• W2048598834 hasConceptScore W2048598834C142462285 @default.
• W2048598834 hasConceptScore W2048598834C159047783 @default.
• W2048598834 hasConceptScore W2048598834C197934379 @default.
• W2048598834 hasConceptScore W2048598834C2522874641 @default.
• W2048598834 hasConceptScore W2048598834C2777068322 @default.
• W2048598834 hasConceptScore W2048598834C2777869810 @default.
• W2048598834 hasConceptScore W2048598834C2778375690 @default.
• W2048598834 hasConceptScore W2048598834C2778414717 @default.
• W2048598834 hasConceptScore W2048598834C2779778239 @default.
• W2048598834 hasConceptScore W2048598834C2780524789 @default.
• W2048598834 hasConceptScore W2048598834C2780593183 @default.
• W2048598834 hasConceptScore W2048598834C2781413609 @default.
• W2048598834 hasConceptScore W2048598834C2781432083 @default.
• W2048598834 hasConceptScore W2048598834C2993143319 @default.
• W2048598834 hasConceptScore W2048598834C3013748606 @default.
• W2048598834 hasConceptScore W2048598834C71924100 @default.
• W2048598834 hasLocation W20485988341 @default.
• W2048598834 hasLocation W20485988342 @default.
• W2048598834 hasLocation W20485988343 @default.
• W2048598834 hasLocation W20485988344 @default.
• W2048598834 hasOpenAccess W2048598834 @default.
• W2048598834 hasPrimaryLocation W20485988341 @default.
• W2048598834 hasRelatedWork W1841555244 @default.
• W2048598834 hasRelatedWork W1886755341 @default.
• W2048598834 hasRelatedWork W1968543449 @default.

• next